Lung Cancer
Lung cancer in brief
Lung cancer, also called bronchial carcinoma, is one of the most common cancers worldwide. The most important risk factor is smoking. Each year, about 57,000 people in Germany develop lung cancer, with men affected somewhat more often than women. Lung cancer is a good example of how much cancer medicine has changed. There are essentially two forms: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Today, various subtypes are also known, each with its own specific treatments.
Lung cancer at a glance
- New cases in Germany
- About 57,000 per year, men somewhat more often than women
- Most important risk factor
- Smoking, including secondhand smoke
- Two main forms
- Small cell (SCLC) and non-small cell lung cancer (NSCLC)
- Most common type
- Adenocarcinoma, at about 44 %
What exactly is lung cancer?
Lung cancer develops when cells of the lung tissue become abnormal and multiply uncontrollably. As the cancer grows over time, it can crowd out healthy lung tissue and so make it harder for the lungs to work – that is, to breathe. As the disease progresses, cancer cells can spread through the blood or lymphatic system and settle in other organs (metastases). Various forms of lung cancer can be distinguished. The most common is adenocarcinoma at about 44 %, followed by squamous cell carcinoma at about 21 % and small cell lung cancer at about 15 %.
Why do I have lung cancer?
In principle, anyone can develop lung cancer. Cancer develops when the genetic material of a cell is damaged and the cell then multiplies uncontrollably. Smoking tobacco – in any form – as well as secondhand smoke are the most important risk factors for lung cancer, because tobacco smoke contains many substances that damage cells. In women, about eight out of ten, and in men nine out of ten lung cancers can be traced back to smoking. Other substances, such as the radioactive noble gas radon in homes, asbestos, arsenic, or diesel exhaust, can also cause lung cancer; for this reason, lung cancer is recognized in Germany as an occupational disease after work-related exposure to certain substances. However, lung cancer can also affect people who have never smoked or been exposed to harmful substances. Sometimes the damage to the genetic material simply occurs by chance.
Symptoms of lung cancer
In its early stages, lung cancer often causes no symptoms. When symptoms do occur, they are often nonspecific at first, such as weight loss, fever, or night sweats. Somewhat more specific symptoms that can occur with lung cancer are:
- persistent cough, sometimes with blood (coughing up blood)
- shortness of breath
- chest pain
- hoarseness or difficulty swallowing
A special feature of lung cancer is the occurrence of so-called paraneoplastic syndromes. These are side effects of the cancer that can occur in addition to the symptoms caused by the growth of the tumor or metastases. They are usually caused by messenger substances released by the tumor, or by a reaction of the immune system.
These symptoms can also have many other causes. If they are new or last longer than a few weeks, please have them checked by a doctor.
Since April 2026, people at increased risk, such as long-term smokers between 50 and 75 years of age, have been able to take part in a lung cancer screening program, in which a low-dose computed tomography (CT) scan of the lungs is performed once a year.
When is lung cancer treated?
The treatment decision takes into account the type of tumor, the stage (how far it has spread), the patient's general condition, lung function, and existing other illnesses. As a rule, treatment begins soon after diagnosis, because the cancer – especially small cell lung cancer – grows quickly.
How is lung cancer treated?
The treatment of lung cancer depends on its type and stage. In most cases, how to proceed is discussed in a tumor board with specialists from various disciplines. The most important treatment options are:
- Surgery: The tumor is removed together with the surrounding lung tissue. This is usually only possible if the tumor was detected early and has not yet spread.
- Radiation therapy: Targeted radiation is used to kill cancer cells. It can be used instead of surgery or in addition to other treatments.
- Chemotherapy: Platinum-based chemotherapy remains an important foundation, because it inhibits the division of tumor cells. Today, it is usually combined with immunotherapy.
- Targeted therapy: Some cancer cells have certain changes in their genetic material (e.g. in the EGFR or ALK genes). A tissue sample (biopsy) can be used to determine these features of the tumor, which can then be treated specifically with tablets.
- Immunotherapy: These drugs (checkpoint inhibitors) release a brake on the immune system and so help it to recognize and fight the cancer cells.
How exactly have clinical trials changed the treatment landscape for lung cancer?
Lung cancer is treated fundamentally differently today than it was 20 years ago. In the past, chemotherapy was the treatment of choice – despite its limited effect and severe side effects. Today we know that lung cancer must be viewed in a more differentiated way and treated in different ways. Surgery is crucial for a curative treatment approach; however, its results can be improved by additionally using chemotherapy, targeted therapies, or immunotherapies before surgery (neoadjuvant) or after it (adjuvant). The following trials relate to non-small cell lung cancer.
- In 2009, the IPASS trial showed that a targeted tablet therapy (gefitinib) prolongs the time without tumor progression compared with chemotherapy in patients whose tumor carries a specific genetic change (EGFR mutation) – these were 261 of the more than 1,200 participants in total. This showed that a treatment tailored to the characteristics of the tumor is beneficial. (DOI: 10.1056/NEJMoa0810699)
- In 2016, the KEYNOTE-024 trial showed that an immunotherapy (pembrolizumab) prolongs survival without tumor progression compared with chemotherapy in 305 patients with a high PD-L1 score (at least 50 %). The 5-year analysis in 2021 was also able to show that markedly more patients survived long-term with immunotherapy than with chemotherapy alone (around 32 % versus 16 %). (DOI: 10.1056/NEJMoa1606774, 10.1200/JCO.21.00174)
- In 2022, the CheckMate-816 trial was one of the first large trials able to show that an immunotherapy (nivolumab) plus chemotherapy before surgery markedly improves results. A total of 358 patients were enrolled, 179 of whom received the additional immunotherapy before surgery. In around a quarter of them, no living tumor could be detected in the surgical specimen any more, and the time without tumor progression was markedly prolonged compared with chemotherapy alone. (DOI: 10.1056/NEJMoa2202170)
These trials show how clinical research has changed the treatment of lung cancer step by step: instead of one therapy for everyone, treatment today is tailored to the characteristics of the tumor – with the result that many of those affected live longer and more often without relapse. Interested in taking part in clinical trials? Then take a look here at the current trials in Germany.
This information is not a substitute for a conversation with your doctor.
Last updated:
Sources (9)
- Zentrum für Krebsregisterdaten (RKI) · Lungenkrebs (opens in a new tab)
- Onkopedia-Leitlinie · Lungenkarzinom, nicht-kleinzellig (NSCLC) (opens in a new tab)
- Onkopedia-Leitlinie · Lungenkarzinom, kleinzellig (SCLC) (opens in a new tab)
- Krebsinformationsdienst (DKFZ) · Lungenkrebs (opens in a new tab)
- Krebsinformationsdienst (DKFZ) · Lungenkrebs: Symptome und Früherkennung (opens in a new tab)
- Mok TS et al.: Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma · N Engl J Med 2009 (opens in a new tab)IPASS
- Reck M et al.: Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer · N Engl J Med 2016 (opens in a new tab)KEYNOTE-024
- Reck M et al.: Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% · J Clin Oncol 2021 (opens in a new tab)KEYNOTE-024
- Forde PM et al.: Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer · N Engl J Med 2022 (opens in a new tab)CheckMate-816